London: Hikma Pharmaceuticals has confirmed a leadership change after announcing that chief executive Riad Mishlawi is stepping down from his role and leaving the board.
The London-listed pharmaceuticals group said its executive chairman and former long-serving chief executive, Said Darwazah, has assumed CEO responsibilities with immediate effect. Hikma added that it will begin a formal search for a new permanent chief executive in due course.
Leadership Transition Confirmed
The company said the decision was reached by mutual agreement and stressed that its strategic priorities remain unchanged. Darwazah, who previously led the group through periods of international expansion and portfolio growth, is expected to provide continuity during the transition.
Mishlawi said it had been an honour to lead the company and thanked colleagues for their support as he steps away from executive responsibilities.
2025 Outlook Reaffirmed
Crucially for investors, Hikma confirmed that its group guidance for 2025 remains unchanged. The company said trading continues in line with expectations, signalling that the leadership change does not reflect any deterioration in performance or outlook.
The reassurance is likely to be welcomed by markets, particularly as Hikma operates across highly regulated pharmaceutical segments in the US, Europe, and emerging markets.
What Comes Next
The board said it will launch a global search for a new chief executive while Darwazah oversees day-to-day leadership. Further governance updates are expected to be disclosed in line with UK regulatory requirements.
Hikma is scheduled to report its full-year 2025 results early next year, which will provide investors with clearer insight into performance during the transition period.
For more details, see the company’s official announcement on the Hikma Pharmaceuticals website .
You May Also Like
Reserve Bank Governor Talks Market Down as ANZ Hikes Mortgage Rates
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
